Genmab — Februar 2024
-
Det var vist aktieprogrammet til ledelsen, der blev hentydet til...
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY
) for Difficult-to https://www.proinvestor.com/investornyt/1123507/us-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-epcoritamab-epkinly-for-difficult-to -
Det må vi håbe - indtil videre lader det ikke til, at de tomme kalorier fra regnskabet kan opveje det generelle udsalg af aktien
-
...det her er vel lidt det modsatte scenarie?
-
bekymringerne er allerede blevet til noget
-
hvorfor skulle han begynde nu?
-
Kyso, the best is yet to come, investment in our own pipeline, targeted m&a - alt sammen tomme ord
-
og nu skal vi have et aktietilbagekøbsprogram, for at redde et druknenede warrantprogram ud af det dybe vand
-
de penge skulle jo bruges på udvikling
-
ud i det blå - 9% cagr for en virksomhed der bryster sig af at være noget særligt....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind